Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES Copy as markdown (a)The following documents are filed as part of this Annual Report:
Financial Statements.
The consolidated financial statements listed in Part II, Item 8 of this Annual Report.
Financial Statement Schedules.
Schedule II – Valuation and Qualifying Accounts .
Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.
Exhibits.
Exhibit Number Exhibit Description Incorporated by Reference Provided Herewith Form File No. Date of First Filing Exhibit Number 3. 1 Restated Certificate of Incorporation of DexCom, Inc. 8-K 000-51222 June 10, 2022 3.1 3. 2 Amended and Restated Bylaws of DexCom, Inc. 8-K 000-51222 May 21, 2021 3.3 4. 1 Form of Specimen Certificate for DexCom, Inc. common stock. S-1/A 333-122454 March 24, 2005 4.01 4. 2 Indenture, dated November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023). 8-K 000-51222 December 3, 2018 4.1 4. 3 Indenture, dated May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due 2025). 8-K 000-51222 May 15, 2020 4.1 4.4 Indenture, dated May 5, 2023, between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028). 8-K 000-51222 May 5, 2023 4.1 4.5 Description of Securities Registered Under Section 12 of the Exchange Act. X 10.1* Offer letter between DexCom, Inc. and Kevin Sayer, dated May 3, 2011. 10-Q 000-51222 August 3, 2011 10.28 10.2 Sublease between DexCom, Inc. and Entropic Communications, LLC , dated February 1, 2016. 10-Q 000-51222 April 27, 2016 10.36 10.3* DexCom, Inc. Executive Deferred Compensation Plan. 8-K 000-51222 June 4, 2019 10.02 10.4** Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019. 10-K 000-51222 February 13, 2020 10.40
10.5* Form of Indemnity Agreement between DexCom, Inc. and each of its directors and executive officers. 10-K 000-51222 February 11, 2021 10.43 10.6* DexCom, Inc. Incentive Bonus Plan. 8-K 000-51222 March 17, 2021 10.1 10.7 Second Amended and Restated Credit Agreement dated October 13, 2021 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent. 10-K 000-51222 February 14, 2022 10.39 10.8 Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P., as amended on August 18, 2010 and October 1, 2014. 10-K 000-51222 February 9, 2023 10.09 10.9** Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019, as amended on October 21, 2019, May 25, 2021, and December 23, 2022. 10-K 000-51222 February 9, 2023 10.18 10.10 * DexCom, Inc. Amended and Restated Severance and Change in Control Plan. 8-K 000-51222 May 19, 2023 10.1 10.11 First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc. and JPMorgan Chase Bank National Association. 10-Q 000-51222 July 27, 2023 10.06 10.12* 2015 Employee Stock Purchase Plan and forms of subscription agreements. X 10.13* Amended and Restated 2015 Equity Incentive Plan and forms of award agreements. X 10.14** Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC). X 19.1* Procedures and Guidelines Governing Securities Trades by Company Personnel . X 21.01 List of Subsidiaries. X 23.01 Consent of Independent Registered Public Accounting Firm. X 24.01 Power of Attorney (see signature page of this Form 10-K). X 31.01 Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). X 31.02 Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). X
* Represents a management contract or compensatory plan, contract or arrangement. ** Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. *** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference.
Previous: Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES · Next: Item 16. FORM 10-K SUMMARY
filings.tools